Preparation of platelet pellet lysate and its use for treating neurological disorders

Patent metadata

Field	Value
Publication number	US-12280074-B2
Application number	US-201716087471-A
Country	US
Kind code	B2
Filing date	Mar 23, 2017
Priority date	Mar 23, 2016
Publication date	Apr 22, 2025
Grant date	Apr 22, 2025

Abstract

A process for preparing a modified heat-treated platelet pellet lysate, said process comprising the steps of: a) Providing a platelet pellet lysate, b) Heat-treating the platelet pellet lysate at a temperature of 55° C. to 65° C. during 20 to 40 minutes, c) Purifying the heat-treated platelet pellet lysate of step b) so as to obtain a modified heat treated platelet pellet lysate having a total protein content of less than 70% of the total protein content of the platelet pellet lysate of step a).

First claim

The invention claimed is:

1. A method for treating a neurological disorder selected from Parkinson's disease and amyotrophic lateral sclerosis, comprising a step of administering an effective amount of a platelet pellet lysate which is modified by a heat treatment at a temperature of 55° C. to 65° C. for 20 to 40 minutes to a patient in need thereof, said lysate having a total protein content of less than 70 % of the total protein content of non-heated platelet pellet lysate, wherein the platelet pellet lysate is prepared using a method comprising steps of:
i. providing a platelet concentrate from human blood;
ii. centrifuging the platelet concentrate to obtain a platelet pellet and a plasma supernatant;
iii. removing the plasma supernatant and suspending the platelet pellet;
iv. subjecting the suspended platelet pellet to freeze/thaw cycles to lyse platelets of the suspended platelet pellet and obtain a suspension; and
v. removing cell debris of the suspension obtained in step iv by centrifugation to obtain a platelet pellet lysate.

2. The method according to claim 1 , wherein the platelet pellet lysate is administered by intrathecal, intraocular, intranasal or intra cerebroventricular route.

3. The method of claim 1 , wherein said platelet pellet lysate is administered by intra cerebroventricular route.

4. The method of claim 1 , wherein said platelet pellet lysate is administered with a pump.

5. The method of claim 1 , wherein said platelet pellet lysate has a total protein content of less than 60% of the total protein content of non heat-treated platelet pellet lysate.

6. The method of claim 1 , wherein said platelet pellet lysate has a total protein content of less than 50% of the total protein content of non heat-treated platelet pellet lysate.

7. The method of claim 1 , wherein said platelet pellet lysate is administered into the right lateral ventricle.

8. The method of claim 1 , wherein said platelet pellet lysate is administered into the third ventricle.

9. A method for treating Parkinson's disease, comprising a step of administering an effective amount of a platelet pellet lysate which is modified by a heat treatment at a temperature of 55°° C. to 65° C. for 20 to 40 minutes to a patient in need thereof, said lysate having a total protein content of less than 70 % of the total protein content of non-heated platelet pellet lysate, wherein the platelet pellet lysate is prepared using a method comprising steps of:
i. providing a platelet concentrate from human blood;
ii. centrifuging the platelet concentrate to obtain a platelet pellet and a plasma supernatant;
iii. removing the plasma supernatant and suspending the platelet pellet;
iv. subjecting the suspended platelet pellet to freeze/thaw cycles to lyse platelets of the suspended platelet pellet and obtain a suspension; and
v. removing cell debris of the suspension obtained in step iv by centrifugation to obtain a platelet pellet lysate.

10. The method according to claim 9 , wherein the platelet pellet lysate is administered by intrathecal, intraocular, intranasal or intra cerebroventricular route.

11. The method of claim 9 , wherein said platelet pellet lysate has a total protein content of less than 60% of the total protein content of non heat-treated platelet pellet lysate.

12. The method of claim 9 , wherein said platelet pellet lysate has a total protein content of less than 50% of total protein content of non heat-treated platelet pellet lysate.

13. The method of claim 9 , wherein said platelet pellet lysate is administered into the right lateral ventricle.

14. The method of claim 9 , wherein said platelet pellet lysate is administered into the third ventricle.

15. A method for treating amyotrophic lateral sclerosis, comprising a step of administering an effective amount of a platelet pellet lysate which is modified by a heat treatment at a temperature of 55° C. to 65° C. for 20 to 40 minutes to a patient in need thereof, said lysate having a total protein content of less than 70% of the total protein content of non-heated platelet pellet lysate, wherein the platelet pellet lysate is prepared using a method comprising steps of:
i. providing a platelet concentrate from human blood;
ii. centrifuging the platelet concentrate to obtain a platelet pellet and a plasma supernatant;
iii. removing the plasma supernatant and suspending the platelet pellet;
iv. subjecting the suspended platelet pellet to freeze/thaw cycles to lyse platelets of the suspended platelet pellet and obtain a suspension; and
v. removing cell debris of the suspension obtained in step iv by centrifugation to obtain a platelet pellet lysate.

16. The method according to claim 15 , wherein the platelet pellet lysate is administered by intrathecal, intraocular, intranasal or intra cerebroventricular route.

17. The method of claim 15 , wherein said platelet pellet lysate has a total protein content of less than 60% of the total protein content of non heat-treated platelet pellet lysate.

18. The method of claim 15 , wherein said platelet pellet lysate has a total protein content of less than 50% of total protein content of non heat-treated platelet pellet lysate.

19. The method of claim 15 , wherein said platelet pellet lysate is administered into the right lateral ventricle.

20. The method of claim 15 , wherein said platelet pellet lysate is administered into the third ventricle.

21. The method according to claim 1 , wherein the platelet pellet lysate is modified by the heat treatment for 30 minutes.

22. The method according to claim 1 , wherein the platelet pellet lysate is modified by the heat treatment at 56° C.

23. The method according to claim 21 , wherein the platelet pellet lysate is modified by the heat treatment at 56° C.

24. The method according to claim 1 , wherein following the heat treatment the platelet pellet lysate is purified by centrifugation or filtration.

25. The method according to claim 23 , wherein following the heat treatment, the platelet pellet lysate is purified by centrifugation or filtration.

Assignees

• Centre Hospitalier Regional Et Univ De Lille Chru
• Univ Lille
• Univ Du Littoral Cote Dopale
• Inst Nat Sante Rech Med
• Univ Taipei Medical

Inventors

• Devos David
• Burnouf Thierry
• Devedjian Jean-Christophe
• Chou Ming-Li

Classifications

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K35/19 Primary

  Platelets; Megacaryocytes · CPC title